Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain

Abstract Background The efficacy of ALO-02, an abuse-deterrent formulation containing extended-release oxycodone and sequestered naltrexone, in the treatment of chronic low back pain (CLBP) was studied in a 12-week randomized controlled trial. Primary efficacy endpoint results have been published pr...

Повний опис

Бібліографічні деталі

Автори:	Arnold J. Weil, Elizabeth T. Masters, Alexandra I. Barsdorf, Almasa Bass, Glenn Pixton, Jacquelyn G. Wilson, Gernot Wolfram
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMC 2017-10-01
Серія:	Health and Quality of Life Outcomes
Предмети:	Abuse-deterrent opioids Patient-reported outcomes Chronic low back pain Naltrexone Oxycodone and extended-release opioid
Онлайн доступ:	http://link.springer.com/article/10.1186/s12955-017-0749-y
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!